Respiratory Tract Infections
Treatment of community-acquired pneumonia (CAP), including infections associated with concurrent bacteremia, caused by susceptible Streptococcus pneumoniae.    
Treatment of CAP caused by susceptible Staphylococcus aureus (methicillin-susceptible [oxacillin-susceptible] strains only).     Also recommended for treatment of CAP caused by methicillin-resistant S. aureus† (MRSA; also known as oxacillin-resistant S. aureus or ORSA).  
Treatment of nosocomial pneumonia caused by susceptible S. aureus (including MRSA) or S. pneumoniae.   
Not indicated for treatment of respiratory tract infections caused by gram-negative bacteria. It is imperative that an anti-infective active against gram-negative bacteria be used concomitantly if documented or presumed pathogens include gram-negative bacteria.
For information regarding treatment of pneumonia, including infections caused by MRSA, consult current IDSA clinical practice guidelines available at [Web].  
Skin and Skin Structure Infections
Treatment of uncomplicated skin and skin structure infections caused by susceptible S. aureus (methicillin-susceptible [oxacillin-susceptible] strains only) or S. pyogenes (group A β-hemolytic streptococci, GAS).  
Treatment of complicated skin and skin structure infections (including diabetic foot infections), without concurrent osteomyelitis, caused by susceptible S. aureus (including MRSA), S. pyogenes, or S. agalactiae (group B streptococci, GBS).    
Not evaluated for use in the treatment of decubitus ulcers. 
Not indicated for treatment of skin and skin structure infections caused by gram-negative bacteria. It is imperative that an anti-infective active against gram-negative bacteria be used concomitantly if the documented or presumed pathogens include gram-negative bacteria.
For information regarding treatment of skin and skin structure infections, including infections caused by MRSA, consult current IDSA clinical practice guidelines available at [Web].  
Vancomycin-resistant Enterococcus faecium Infections
Treatment of infections caused by susceptible vancomycin-resistant Enterococcus faecium, including infections associated with concurrent bacteremia.  
Has been used for treatment of native valve or prosthetic valve infective endocarditis† caused by vancomycin-resistant or multidrug-resistant E. faecium. AHA recommends that patients with infective endocarditis attributable to enterococci resistant to penicillins, aminoglycosides, and vancomycin be managed by a team of specialists in infectious disease, cardiology, cardiovascular surgery, clinical pharmacy, and, if necessary, pediatrics.
For information on diagnosis and management of infective endocarditis and its complications, including anti-infective treatment of enterococcal endocarditis, consult current AHA guidelines available at [Web].
CNS Infections
Has been recommended as an alternative to vancomycin for treatment of CNS infections caused by MRSA† (e.g., meningitis†, brain abscess†, subdural empyema†, spinal epidural abscess†). (See Pediatric Use under Cautions.)
For information regarding treatment of CNS infections caused by MRSA, consult current IDSA clinical practice guidelines available at [Web].
